TISIDB

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus.
Domain	PF06333 Mediator complex subunit 13 C-terminal PF11597 Mediator complex subunit 13 N-terminal
Function	Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors.

> Gene Ontology [ TOP ]
Biological Process	GO:0006352 DNA-templated transcription, initiation GO:0006367 transcription initiation from RNA polymerase II promoter GO:0009755 hormone-mediated signaling pathway GO:0010469 regulation of receptor activity GO:0030518 intracellular steroid hormone receptor signaling pathway GO:0030521 androgen receptor signaling pathway GO:0030522 intracellular receptor signaling pathway GO:0042632 cholesterol homeostasis GO:0043401 steroid hormone mediated signaling pathway GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0048545 response to steroid hormone GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0055088 lipid homeostasis GO:0055090 acylglycerol homeostasis GO:0055092 sterol homeostasis GO:0070328 triglyceride homeostasis GO:0071383 cellular response to steroid hormone stimulus GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:1904167 regulation of thyroid hormone receptor activity GO:1904168 negative regulation of thyroid hormone receptor activity GO:2000272 negative regulation of receptor activity
Molecular Function	GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding GO:0001104 RNA polymerase II transcription cofactor activity GO:0003713 transcription coactivator activity GO:0008134 transcription factor binding GO:0030374 ligand-dependent nuclear receptor transcription coactivator activity GO:0035257 nuclear hormone receptor binding GO:0042809 vitamin D receptor binding GO:0046966 thyroid hormone receptor binding GO:0051427 hormone receptor binding
Cellular Component	GO:0016592 mediator complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04919 Thyroid hormone signaling pathway
Reactome	R-HSA-1266738: Developmental Biology R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-1989781: PPARA activates gene expression R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) R-HSA-381340: Transcriptional regulation of white adipocyte differentiation

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04919 Thyroid hormone signaling pathway

Reactome

R-HSA-1266738: Developmental Biology
R-HSA-535734: Fatty acid, triacylglycerol, and ketone body metabolism
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1989781: PPARA activates gene expression
R-HSA-400206: Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MED13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MED13 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: 1.29; FDR: 0.000150	Sensitive to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MED13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.023	0.935
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.002	0.999
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.046	0.964
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.231	0.457
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.18	0.944
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.299	0.93
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.214	0.616
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.109	0.954
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.33	0.875
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.356	0.732
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.832	0.581
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.096	0.0332

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MED13 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	11.8	-4.7	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	33.3	-23.3	0.423
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	25.9	2.7	23.2	0.00131
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	25.9	3.4	22.5	0.0036
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MED13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MED13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MED13. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MED13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MED13 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MED13 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MED13
Name	mediator complex subunit 13
Aliases	KIAA0593; TRAP240; THRAP1; thyroid hormone receptor associated protein 1; ARC250; DRIP250; HSPC221; activato ......
Chromosomal Location	17q22-q23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MED13 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MED13